

## Hypoport AG


Buy → | Target price : 163.00 EUR

Price (24/04/2018): 153.00 EUR | Upside: 7 %

# **Est.chg 2018e 2019e**EPS - -

# Preliminary Q1 2018 results: Sales significantly above our estimate, EBIT in line with our expectation

Publication date 25.04.2018 16:12 Writing date 25.04.2018 16:11



—Hypoport AG —Hypoport AG Relative to Property, holdings, other fi (Rebased)

Source: Oddo BHF Securities. Fininfo

Source . Oddo brir Securitie	3, 1 11111110		
Capital			
HYQ GY   HYQGn.DE			
Market Cap (EURm)			910
Enterprise value (EURm)			894
Extrema 12 months		96.64	161.0
Free Float (%)			56.1
Performance (%)	1m	3m	12m
Absolute	13.7	14.2	66.1
Perf. rel. Country Index	8.5	19.4	67.4
Perf. rel. Property, holding	10.0	17.9	56.8
P&L	12/18e	12/19e	12/20e
Sales (FLIRm)	229	264	300

Sales (EURm)	229	264	300
EBITDA (EURm)	37.5	44.4	52.0
Current EBIT (EURm)	29.2	34.5	40.4
Attr. net profit (EURm)	22.9	27.3	32.1
Adjusted EPS (EUR)	3.86	4.59	5.40
Dividend (EUR)	0.00	0.00	0.00
P/E (x)	39.7	33.4	28.4
` '			
P/B (x)	8.6	6.9	5.5
Dividend Yield (%)	0.0	0.0	0.0
FCF yield (%)	1.2	1.6	2.1
EV/Sales (x)	3.96	3.39	2.92
EV/EBITDA (x)	24.2	20.1	16.8
EV/Current EBIT (x)	31.1	25.9	21.6
Gearing (%)	-8	-18	-26
Net Debt/EBITDA(x)	ns	ns	ns

#### Next Events

03.05.2018 Q1 Results
04.05.2018 Annual General meeting
06.08.2018 H1 Results
05.11.2018 Q3 Results

## Preliminary Q1 2018 figures

Q1 sales reached c.€ 60m, significantly above our estimate (€ 57.1m).

EBIT came in at € 7.5m, and in line with our estimate (€ 7.6m). The EBIT margin of roughly 12.5% is close to our full-year estimate (12.7%).

The German market for new mortgage finance increased by 2.2% overall in the period from January to February 2018, according to Deutsche Bundesbank. This growth was driven by the rise in interest rates at the beginning of the year. We assume that not only Hypoport's Credit Platform and its Private Clients segment, but also its Institutional Clients segment, benefitted from this development, especially considering the relative speed of the interest rate increase in Q1.

### Hypoport: Preliminary Q1 2018 figures (€ m)

	Actual	ODDO BHF estimates	∆ Actual vs estimates	2016
Sales	c. 60	57.1	+5%	47.7
EBIT	c. 7.5	7.6	-1%	7.0

Source: Oddo BHF Securities, Hypoport AG

### Company on track to meet its guidance and our estimates

Even if sales in the remaining quarters of 2018 only stay at the Q1 level (€ 60m) – instead of increasing from quarter to quarter as is usually the case – Hypoport's full-year sales would still achieve the upper end of its guidance range (€ 220-240m). We thus may have to revisit our 2018e sales estimate after we analyse in more detail segment sales performances based on the full Q1 2018 report to be issued on 3 May.

Regarding EBIT, we currently see no reason why the company should miss our full-year estimate ( $\leq$  29.2m) or even its guidance ( $\leq$  26-31m).

#### Buy recommendation confirmed

After the announcement of the Q1 preliminaries, we initially saw a very volatile share price reaction – probably due to technical reasons – and then a stabilisation at a level about 3% below yesterday's closing price. In our view, this market reaction is not justified. We confirm our Buy recommendation on the basis of a target price of € 163.

Martin Decot (Analyst) +49 (69) 71 83 736 martin.decot@oddo-bhf.com



HYQGn.DE   HYQ GY	1	Buy				Price	153.00EUR	
Financial Services   Germany	ı	Upside	6.54%			TP	163.00EUR	
PER SHARE DATA (EUR)	12/13	12/14	12/15	12/16	12/17	12/18e	12/19e	12/20e
Adjusted EPS Reported EPS	0.51 <b>0.51</b>	0.96 <b>0.96</b>	2.63 <b>2.63</b>	3.00 <b>3.00</b>	3.10 <b>3.10</b>	3.86 <b>3.86</b>	4.59 <b>4.59</b>	5.40 <b>5.40</b>
Growth in EPS(%)	ns	88.0%	ns	14.2%	3.3%	24.5%	18.9%	17.6%
Net dividend per share	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
FCF to equity per share	0.67	0.37	3.24	1.50	-0.40	1.77	2.49	3.20
Book value per share Number of shares market cap	5.34 6.14	6.29 6.14	8.68 6.04	10.62 6.01	13.90 5.94	17.75 5.95	22.34 5.95	27.73 5.95
Number of diluted shares	6.14	6.14	6.04	6.01	5.94	5.95	5.95	5.95
VALUATION	12/13	12/14	12/15	12/16	12/17	12/18e	12/19e	12/20e
12m highest price 12m lowest price	10.46 7.03	13.78 8.67	80.50 12.16	97.00 53.59	161 77.48	153 120		
(*) Reference price	8.27	11.01	33.28	75.07	114	153	153	153
Capitalization	50.7	67.6	201	451	676	910	910	910
Restated Net debt	5.9	3.9	-13.5	-11.7	2.0	-8.5	-23.3	-42.4
Minorities (fair value)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial fixed assets (fair value) Provisions	0.0 0.5	0.0	0.0	0.0 10.9	0.0	0.0 7.1	0.0 7.1	0.0 7.1
Enterprise Value	57.1	1.0 <b>72.5</b>	2.1 <b>190</b>	451	7.1 <b>685</b>	908	894	875
P/E (x)	16.1	11.4	12.7	25.0	36.7	39.7	33.4	28.4
P/CF (x)	5.2	4.4	5.7	16.0	27.3	29.4	24.7	21.0
Net Yield (%)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF yield (%)	8.1%	3.3%	9.7%	2.0%	ns	1.2%	1.6%	2.1%
P/B incl. GW (x) P/B excl. GW (x)	1.55 1.55	1.75 1.75	3.84 3.84	7.07 7.07	8.18 8.18	8.62 8.62	6.85 6.85	5.52 5.52
EV/Sales (x)	0.58	0.65	1.36	2.88	3.52	3.96	3.39	2.92
EV/EBITDA (x)	7.0	5.7	7.6	15.9	22.7	24.2	20.1	16.8
EV/EBIT (x)	14.5	9.1	9.8	19.4	29.4	31.1	25.9	21.6
(*) historical average price PROFIT AND LOSS (EURm)	12/13	12/14	12/15	12/16	12/17	12/18e	12/19e	12/20e
Sales	98	112	139	157	195	229	264	300
EBITDA	8.1	12.7	25.1	28.3	30.1	37.5	44.4	52
Depreciations	-4.2	-4.8	-5.8	-5.1	-6.8	-8.3	-9.9	-11.5
Current EBIT Published EBIT	<b>3.9</b> 3.9	<b>7.9</b> 7.9	<b>19.3</b> 19.3	<b>23.2</b> 23.2	<b>23.3</b> 23.3	<b>29.2</b> 29.2	<b>34.5</b> 34.5	<b>40.4</b> 40.4
Net financial income	-0.9	-0.7	-0.1	-0.4	-0.3	-0.5	-0.4	-0.2
Corporate Tax	0.1	-1.3	-3.2	-4.8	-4.6	-5.8	-6.9	-8.1
Net income of equity-accounted companies	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Profit/loss of discontinued activities (after tax) Minority interests	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	0.0	0.0 0.0	0.0 0.0	0.0 0.0
Attributable net profit	3.1	5.9	15.9	18.0	18.4	22.9	27.3	32.1
Adjusted attributable net profit	3.1	5.9	15.9	18.0	18.4	22.9	27.3	32.1
BALANCE SHEET (EURm)	12/13	12/14	12/15	12/16	12/17	12/18e	12/19e	12/20e
Goodwill Other intangible assets	0.0 29.6	0.0 31.0	0.0 31.9	0.0 41.7	0.0 56.0	0.0 67.8	0.0 73.0	0.0 78.8
Tangible fixed assets	2.2	2.2	2.6	2.6	4.4	8.3	10.4	12.3
WCR	6.9	9.0	4.9	10.8	27.3	23.8	28.6	33.6
Financial assets	0.8	1.6	1.9	2.3	4.2	4.5	4.9	5.3
Ordinary shareholders equity Minority interests	32.8 0.3	38.6 0.3	52.4 0.3	63.8 0.3	82.6 0.3	106 0.3	133 0.3	165 0.3
Shareholders equity	33.1	38.9	52.7	64.1	82.9	106	133	165
Non-current provisions	0.5	1.0	2.1	4.9	7.1	7.1	7.1	7.1
Net debt	5.9	3.9	-13.5	-11.7	2.0	-8.5	-23.3	-42.4
CASH FLOW STATEMENT (EURm) EBITDA	12/13 8.1	12/14 12.7	12/15 25.1	12/16 28.3	12/17 30.1	12/18e 37.5	12/19e 44.4	12/20e 52.0
Change in WCR	3.7	-3.0	2.9	-7.5	-16.1	-5.0	-4.7	-5.0
Interests & taxes	-1.5	-1.3	-2.9	-3.4	-4.8	-6.3	-7.3	-8.3
Others	-0.5	0.0	1.6	-0.7	-0.6	-0.3	-0.3	-0.4
Operating Cash flow CAPEX	9.9 -5.7	8.4 -6.2	26.7 -7.1	16.7 -7.7	8.7 -11.1	25.9 -15.4	32.1 -17.3	38.3 -19.2
Free cash-flow	4.1	2.2	19.6	9.0	-2.4	10.5	14.8	19.1
Acquisitions / disposals	0.0	0.0	0.0	0.0	-0.5	0.0	0.0	0.0
Dividends	0.0 0.0	0.0 0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net capital increase Others	-1.4	-1.2	-2.3 -4.6	-6.9 3.5	0.0 14.9	0.0 -1.1	0.0 -4.3	0.0 -4.0
Change in net debt	4.2	1.9	17.3	-3.4	-12.5	10.5	14.8	19.1
GROWTH MARGINS PRODUCTIVITY	12/13	12/14	12/15	12/16	12/17	12/18e	12/19e	12/20e
Sales growth Lfl sales growth	11.8% <b>0.0%</b>	14.5% <b>0.0%</b>	23.7% <b>0.0%</b>	12.7% <b>0.0%</b>	24.4% <b>0.0%</b>	17.7% <b>0.0%</b>	14.9% <b>0.0%</b>	13.7% <b>0.0%</b>
Current EBIT growth	23.5%	ns	ns	20.6%	0.3%	25.4%	18.2%	17.0%
Growth in EPS(%)	ns	88.0%	ns	14.2%	3.3%	24.5%	18.9%	17.6%
Net margin	3.2%	5.3%	11.4%	11.5%	9.5%	10.0%	10.3%	10.7%
EBITDA margin Current EBIT margin	8.3% 4.0%	11.3% 7.1%	18.0% 13.9%	18.1% 14.8%	15.5% 12.0%	16.3% 12.7%	16.9% 13.1%	17.3% 13.5%
CAPEX / Sales	-5.8%	-5.5%	-5.1%	-4.9%	-5.7%	-6.7%	-6.6%	-6.4%
WCR / Sales	7.0%	8.0%	3.5%	6.9%	14.0%	10.4%	10.8%	11.2%
Tax Rate	-3.3%	18.2%	16.9%	20.8%	19.9%	20.2%	20.2%	20.2%
Normative tax rate Asset Turnover	-31.1% 2.5	-20.1% 2.8	-28.3% 3.4	-30.3% 3.3	-25.8% 2.7	22.2% 2.4	ns 2.5	79.6% 2.5
ROCE post-tax (normative tax rate)	13.0%	23.6%	60.6%	64.1%	41.1%	24.2%	ns	7.0%
ROCE post-tax hors GW (normative tax rate)	13.0%	23.6%	60.6%	64.1%	41.1%	24.2%	ns	7.0%
ROE	10.1%	16.6%	34.9%	31.0%	25.2%	24.4%	22.9%	21.6%
DEBT RATIOS Gearing	<b>12/13</b> 18%	<b>12/14</b> 10%	<b>12/15</b> -26%	<b>12/16</b> -18%	<b>12/17</b> 2%	<b>12/18e</b> -8%	<b>12/19e</b> -18%	<b>12/20e</b> -26%
Net Debt / Market Cap	0.12	0.06	-0.07	-0.03	0.00	-0.01	-0.03	-0.05
Net debt / EBITDA	0.72	0.31	ns	ns	0.07	ns	ns	ns
EBITDA / net financial charges Source: ODDO BHF Securities, Fininfo	ns	ns						
Course. Obbo bili occultues, i illillio								

#### Hypoport AG Wednesday 25 April 2018



#### · Valuation method

Our target prices are established on a 12-month timeframe and we use three valuation methods to determine them. First, the discounting of available cash flows using the discounting parameters set by the Group and indicated on Oddo BHF' website. Second, the sum-of-the-parts method based on the most pertinent financial aggregate depending on the sector of activity. Third, we also use the peer comparison method which facilitates an evaluation of the company relative to similar businesses, either because they operate in identical sectors (and are therefore in competition with one another) or because they benefit from comparable financial dynamics. A mixture of these valuation methods may be used in specific instances to more accurately reflect the specific characteristics of each company covered, thereby fine-tuning its evaluation.

#### Sensitivity of the result of the analysis/ risk classification:

The opinions expressed in the financial analysis are opinions as per a particular date, i.e. the date indicated in the financial analysis. The recommendation (cf. explanation of the recommendation systematic) can change owing to unforeseeable events which may, for instance, have repercussions on both the company and on the whole industry.

#### · Our stock market recommendations

Our stock market recommendations reflect the RELATIVE performance expected for each stock on a 12-month timeframe. Buy: performance expected to exceed that of the benchmark index, sectoral (large caps) or other (small and mid caps). Neutral: performance expected to be comparable to that of the benchmark index, sectoral (large caps) or other (small and mid caps). Reduce: performance expected to fall short of that of the benchmark index, sectoral (large caps) or other (small and mid caps).

- The prices of the financial instruments used and mentioned in this document are the closing prices.
- All publications by Oddo BHF concerning the companies covered and mentioned in this document are available on the research site: www.oddosecurities.com

#### Recommendation and target price changes history over the last 12 months for the company analysed in this report

Date	Reco	Price Target (EUR)	Price (EUR)	Analyst	
10.04.18	Buy	163.00	139.00	Martin Decot	
15.01.18	Neutral	139.00	131.60	Martin Decot	
30.10.17	Buy	139.00	124.25	Martin Decot	
23.10.17	Neutral	139.00	120.75	Martin Decot	

In accordance with Article 20 of European Regulation No. 596/2014 (Market Abuse Regulation), a list of all recommendations on any financial instrument or issuer that have been disseminated over the past twelve months is available by clicking on the following link Web lien

Recommendation split				
		Buy	Neutral	Reduce
Our whole coverage	(414)	50%	41%	9%
Liquidity providers coverage	(129)	46%	49%	5%
Research service coverage	(58)	57%	38%	5%
Investment banking services	(44)	75%	20%	5%

tisk of conflict of interest :	
Investment banking and/or Distribution	
Has Oddo BHF, managed or co-managed in the past 12 months a public offering of securities for the subject company/ies?	No
Has Oddo BHF, received compensation for investment banking services from the subject company/ies in the past 12 months or expects to receive or intends to seek compensation for investment banking services from the subject company/ies in the last 12 months?	No
Research contract between Oddo group & the issuer	
Oddo BHF and the issuer have agreed that Oddo BHF will produce and disseminate investment recommendations on the said issuer as a service to the issuer	Yes
Liquidity provider agreement and market-making	
At the date of the distribution of this report, does Oddo BHF, act as a market maker or has Oddo BHF, signed a liquidity provider agreement with the subject company/ies?	Yes
Significant equity stake	
Does Oddo BHF, own 5% or more of any class of common equity securities of the subject company/ies?	No
Does the subject company beneficially own 5% or more of any class of common equity of Oddo BHF or its affiliates?	No
Disclosure to Company	
Has a copy of this report; with the target price and/or rating removed, been presented to the subject company/ies prior to its distribution, for the sole purpose of verifying the accuracy of factual statements?	No
Have the conclusions of this report been amended following disclosure to the company/ies and prior its distribution?	No
Additional material conflicts	
Is Oddo BHF, aware of any additional material conflict of interest?	No
Personal conflicts of interest	
Have those responsible for the drafting of the present document acquired securities from the issuer concerned by the present financial analysis?	No
Have those responsible for the drafting of the present document received remuneration directly linked to investment firm service transactions or any other kind of transaction they carry out or any trading commissions they, or any legal person who is part of the same group, receive?	No

Statement of conflict of interests of all companies mentioned in this document may be consulted on Oddo BHF: www.oddosecurities.com

#### Hypoport AG Wednesday 25 April 2018



#### Disclaimer:

Disclaimer for Distribution by ODDO BHF SCA to Non-United States Investors:

This research publication is produced by ODDO BHF Corporate & Markets, a division of ODDO BHF SCA ("ODDO"), which is licensed by the Autorité de Contrôle Prudentiel

et de Résolution (ACPR) and regulated by the Autorité des Marchés Financiers ("AMF").

The research, when distributed outside of the U.S., is intended exclusively for non-U.S. customers of ODDO and cannot be divulged to a third-party without prior written consent of ODDO. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. This research has been prepared in accordance with regulatory provisions designed to promote the independence of investment research. "Chinese walls" (information barriers) have been implemented to avert the unauthorized dissemination of confidential information and to prevent and manage situations of conflict of interest. This research has been prepared in accordance with French regulatory provisions designed to promote the independence of investment research. The recommendation presented in this document is reviewed and updated at least quarterly following each Quarterly Report published by the issuer that is the subject of this Research Report.

At the time of publication of this document, ODDO and/or one of its subsidiaries may have a conflict of interest with the issuer(s) mentioned. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such. Past performances offer no guarantee as to future performances. All opinions expressed in the present document reflect the current context which is subject to change without notice. The views expressed in this Research Report accurately reflect the analyst's personal views about the subject securities and/or issuers and no part of his compensation was, is, or will be directly or indirectly related to the specific views contained in the Research Report. This Research Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax

This Research Report is for institutional investors only. It may not contain information necessary for others to make investment decisions. Consult your financial adviser or an investment professional if you are not an institutional investor.

Disclaimer for Distribution by Oddo New York to United States Investors:

This Research Report is produced by ODDO BHF Corporate & Markets, a division of ODDO. This research is distributed to U.S. investors exclusively by ODDO BHF New York Corporation ("ONY"), MEMBER: FINRA/SIPC, and is intended exclusively for U.S. customers of ONY and cannot be divulged to a third-party without prior written consent of ONY. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. This research has been prepared in accordance with regulatory provisions designed to promote the independence of investment research. "Chinese walls" (information barriers) have been implemented to avert the unauthorized dissemination of confidential information and to prevent and manage situations of conflict of interest. This research has been prepared in accordance with French regulatory provisions designed to promote the independence of investment research. The recommendation presented in this document is reviewed and updated at least quarterly following each Quarterly Report published by the issuer that is the subject of this Research Report.

At the time of publication of this document, ODDO, and/or one of its subsidiaries may have a conflict of interest with the issuer(s) mentioned. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such. Past performances offer no guarantee as to future performances. All opinions expressed in the present document reflect the current context which is subject to change without notice. The views expressed in this Research Report accurately reflect the analyst's personal views about the subject securities and/or issuers and no part of his compensation was, is, or will be directly or indirectly related to the specific views contained in the Research Report. This Research Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice.

This Research Report is for institutional investors only. It may not contain information necessary for others to make investment decisions. Consult your financial adviser or an investment professional if you are not an institutional investor.

#### Rule 15a-6 Disclosure:

Under Rule 15a-6(a)(3), any transactions conducted by ODDO, and/or one of its subsidiaries with U.S. persons in the securities described in this foreign research must be effected through ONY. As a member of FINRA, ONY has reviewed this material for distribution to U.S. persons as required by FINRA Rules 2241(h) applicable to dissemination of research produced by its affiliate ODDO.

- · Neither ONY, ODDO, nor ODDO BHF Corporate & Markets beneficially owns 1% or more of any class of common equity securities of the subject company.
- The research analyst of ODDO BHF Corporate & Markets, at the time of publication of this research report, is not aware, nor does he or she know or have reason to know of any actual, material conflict of interest of himself or herself, ODDO, ODDO BHF Corporate & Markets or ONY, except those mentioned in the paragraph entitled "Risks of Conflicts of Interest.'
- ODDO BHF Corporate & Markets or ODDO may receive or seek compensation for investment banking services in the next 3 months from the subject company of this Research Report, but ONY would not participate in those arrangements.
- · Neither ONY, ODDO, ODDO BHF Corporate & Markets has received compensation from the subject company in the past 12 months for providing investment banking services except those mentioned in the paragraph of "Risks of Conflict of Interest"."
- · Neither ONY, ODDO, ODDO BHF Corporate & Markets has managed or co-managed a public offering of securities for the subject company in the past 12 months except those mentioned in the paragraph of "Risk of Conflict of Interest".
- · ONY does not make (and never has made) markets and, accordingly, was not making a market in the subject company's securities at the time that this research report was published.

Regulation AC: ONY is exempt from the certification requirements of Regulation AC for its distribution to a U.S. person in the United States of this Research Report that is prepared by an ODDO BHF Corporate & Markets research analyst because ODDO has no officers or persons performing similar functions or employees in common with ONY and ONY maintains and enforces written policies and procedures reasonably designed to prevent it, any controlling persons, officers or persons performing similar functions, and employees of ONY from influencing the activities of the third party research analyst and the content of research reports prepared by the third party research analyst.

Contact Information of firm distributing research to U.S. investors: ODDO BHF New York Corporation, MEMBER: FINRA/SIPC, is a wholly owned subsidiary of ODDO BHF SCA; Philippe Bouclainville, President (pbouclainville@oddony.com) 150 East 52nd Street New York, NY 10022 212-481-4002.